Assessment of GARP Expression in Acute and Chronic Coronary Syndrome

NCT07384910 — Not applicable, Not yet recruiting, 600 participants, Université Catholique de Louvain

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Assessment of GARP Expression and Inflammatory Cytokines in Acute and Chronic Coronary Syndrome

Registry	NCT07384910, acronym GARP-CS
Status	Not yet recruiting
Phase	Not applicable
Study type	Interventional; non randomized, parallel, masking: none, basic science
Enrollment	600 (Estimated)
Sponsor	Université Catholique de Louvain (Other); collaborators: Fonds National de la Recherche Scientifique
Conditions	Atheroma; Heart
Interventions	Arterial blood sample (Biological)
Dates	start 2026-02-01 (estimated), primary completion 2028-01-01 (estimated), completion 2028-01-01 (estimated), first posted 2026-02-03, last updated 2026-02-17
Locations	1 site in Belgium

-Summary

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Acute coronary syndrome	Experimental	Biological: Arterial blood sample	This arm includes patients undergoing coronary angiography with a final diagnostic of acute coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.
Chronic coronary syndrome	Experimental	Biological: Arterial blood sample	This arm includes patients undergoing coronary angiography with a final diagnostic of chronic coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.
Control	Experimental	Biological: Arterial blood sample	This arm includes patients undergoing coronary angiography with a final diagnostic of non significant coronary disease. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.

Arterial blood sample (Biological): An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.

+Outcome measures

Primary outcomes

Platelet GARP expression [Throughout the entire study, approximately during 2 years]: The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.

Secondary outcomes

Inflammatory profile [Throughout the entire study, approximately during 2 years]: The inflammatory cytokines (IL-1, IL-6, TNF,...) profile will be determined by multiplex and compared between arms.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Older than 18 years
* Able to give informed consent
* Undergoing coronary angiography.

Exclusion Criteria:

* Patients younger than 18 years
* Unable to give consent
* Pregnancy
* Dialysis

+Locations (1)

Facility	City	Country	Status
Cliniques Universitaires Saint-Luc	Brussels	Belgium

+Investigators

Christophe Beauloye, Medical Degree, Principal investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain